Prospect of a Dopamine Contribution in the Next Generation of Antidepressant Drugs: The Triple Reuptake Inhibitors
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Biogenic amine transporters for serotonin and norepinephrine (5-HT and NE respectively), are major targets for currently available antidepressant drugs, particularly those inhibiting the reuptake of 5-HT and/or NE. Compelling evidence suggest that dopamine (DA) is also involved in the pathophysiology and treatment of depression, leading to the development of a new class of antidepressants: the triple reuptake inhibitors that simultaneously inhibit 5-HT, NE and DA reuptake thereby prolonging their duration of action at postsynaptic levels. Although preclinical studies strongly suggest that triple reuptake inhibitors display antidepressant-like activity in various behavioural paradigms, including the forced swimming and the tail suspension tests, it has yet to be demonstrated that the addition of the dopaminergic component produces more robust effects than single- or dual-acting compounds. Several arguments favour this hypothesis and particularly the observation that DA may promote neurotrophic processes in the adult hippocampus, as 5-HT and NE do. It is thus possible that the stimulation of multiple signalling pathways resulting from the elevation of all three monoamines may account, in part, for an accelerated and/or greater antidepressant response. To predict the efficacy of triple reuptake inhibitors, it is important to take into consideration the existence of dense connections between monoaminergic neurons. Indeed, it is well established that the increase in central dopaminergic transmission regulates the neuronal activity of 5-HT and NE in the dorsal raphe (DR) and locus coeruleus (LC), respectively, while in turn, the ventral tegmental area (VTA), is sensitive to changes in 5-HT and NE release. This review synthetizes the pertinent litterature, focusing on the contribution of DA, to illustrate the rationale for designing improved antidepressants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Depression: a new animal model sensitive to antidepressant treatments
PORSOLT, R. D., LE PICHON, M., & JALFRE, M. (1977) · Nature · doi:10.1038/266730a0 · Cited by 4,451
The tail suspension test: A new method for screening antidepressants in mice
Steru, L., Chermat, R., Thierry, B., & Simon, P. (1985) · Psychopharmacology · doi:10.1007/bf00428203 · Cited by 3,534
Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09104.2000 · Cited by 3,111
A molecular and cellular theory of depression
Duman, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830190015002 · Cited by 2,129
Nibuya, M., Morinobu, S., & Duman, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-11-07539.1995 · Cited by 2,109 · cited 1×
“In particular, given that depression not only results from brain monoamines imbalance but involves other mechanisms such as cellular loss, atrophy, and abnormal neuronal connectivity in many brain areas [29], this review will address the possibility that triple reuptake inhibitors may exert more robust antidepressant…”
BackgroundSwanson, L. W. (1982) · Brain Research Bulletin · doi:10.1016/0361-9230(82)90145-9 · Cited by 1,718 · cited 1×
“In rodents, although only a small percentage of its VTA-derived afferents seem to be dopaminergic [109], DA receptors mainly of the D2-like subtype have been identified in this brain area [110].”
BackgroundNew approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589 · cited 1×
“quately to these agents [12].”
Assessing antidepressant activity in rodents: recent developments and future needs
Cryan, J. F., Markou, A., & Lucki, I. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02017-5 · Cited by 1,551
The role of dopamine in the pathophysiology of depression
Dunlop, B. W., & Nemeroff, C. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.327 · Cited by 1,244 · cited 1×
“central dopaminergic transmission [24], and usually ob-”
The cellular neurobiology of depression
Manji, H. K., Drevets, W. C., & Charney, D. S. (2001) · Nature Medicine · doi:10.1038/87865 · Cited by 1,182 · cited 1×
“In particular, given that depression not only results from brain monoamines imbalance but involves other mechanisms such as cellular loss, atrophy, and abnormal neuronal connectivity in many brain areas [29], this review will address the possibility that triple reuptake inhibitors may exert more robust antidepressant…”
BackgroundUntreated Depression and Hippocampal Volume Loss
Sheline, Y. I., Gado, M. H., & Kraemer, H. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1516 · Cited by 1,180
Pharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939
Ruhé, H. G., Mason, N. S., & Schene, A. H. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001949 · Cited by 861
Essential role of brain-derived neurotrophic factor in adult hippocampal function
Monteggia, L. M., Barrot, M., Powell, C. M., Berton, O., Galanis, V., Gemelli, T., Meuth, S., Nagy, A., Greene, R. W., & Nestler, E. J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402141101 · Cited by 685
Morón, J. A., Brockington, A., Wise, R. A., Rocha, B. A., & Hope, B. T. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-02-00389.2002 · Cited by 681
Adachi, M., Barrot, M., Autry, A. E., Theobald, D., & Monteggia, L. M. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.09.019 · Cited by 380
Origin of dopaminergic innervation of the rat hippocampal formation
Scatton, B., Simon, H., Le Moal, M., & Bischoff, S. (1980) · Neuroscience Letters · doi:10.1016/0304-3940(80)90314-6 · Cited by 323
Cryan, J. F., Page, M. E., & Lucki, I. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0093-5 · Cited by 321
Dias, B. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00198-9 · Cited by 274
Lower dopamine transporter binding potential in striatum during depression
Meyer, J. H., Krüger, S., Wilson, A. A., Christensen, B. K., Goulding, V. S., Schaffer, A., Minifie, C., Houle, S., Hussey, D., & Kennedy, S. H. (2001) · Neuroreport · doi:10.1097/00001756-200112210-00052 · Cited by 269
The role of the brain reward system in depression
Naranjo, C. A., Tremblay, L. K., & Busto, U. E. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00156-7 · Cited by 245 · cited 1×
“Such dopaminergic deficits produce anhedonia and disrupted reward-related behavior, core symptoms of depression, associated with an altered mesocorticolimbic dopaminergic function [34,35].”
BackgroundEntsuah, A. R., Huang, H., & Thase, M. E. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1106 · Cited by 245
Hasler, G., Fromm, S., Carlson, P. J., Luckenbaugh, D. A., Waldeck, T., Geraci, M., Roiser, J. P., Neumeister, A., Meyers, N., Charney, D. S., et al. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.5.521 · Cited by 209 · cited 1×
“In these conditions, dysphoric and anhedonic symptoms appear in healthy volunteers, or are potentiated in depressed patients [36-39].”
BackgroundDopamine D2 receptors in depression measured with single photon emission computed tomography
D'haenen, H. A., & Bossuyt, A. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)91202-5 · Cited by 189 · cited 1×
“Such a reduction in dopaminergic transmission could account for adaptive mechanisms usually observed in depressed patients, such as an increase in D2/D3 receptor binding sites [46-48] or a reduced DA transporter (DAT) activity [49].”
BackgroundClinical and psychometric correlates of dopamine D2 binding in depression
SHAH, P. J., OGILVIE, A. D., GOODWIN, G. M., & EBMEIER, K. P. (1997) · Psychological Medicine · doi:10.1017/s0033291797005382 · Cited by 170
Dopaminergic mechanism of antidepressant action in depressed patients
Willner, P., Hale, A. S., & Argyropoulos, S. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.12.010 · Cited by 169 · cited 1×
“Furthermore, it has been recently demonstrated that the acute administration of a low dose of the selective dopamine D2-like receptor antagonists sulpiride caused a substantial reoccurrence of depressed mood in SSRIs treated patients [80].”
BackgroundIncreasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs
Malberg, J., & Schechter, L. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053382223 · Cited by 167
Bodkin, J. A., Lasser, R. A., Wines, J. D., Gardner, D. M., & Baldessarini, R. J. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0401 · Cited by 159
Serotonin–dopamine interaction: electrophysiological evidence
DIGIOVANNI, G., DIMATTEO, V, PIERUCCI, M., & ESPOSITO, E. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00903-5 · Cited by 151 · cited 1×
“Although, serotonergic and noradrenergic inputs are known to modulate the neuronal activity of DA neurons in the VTA (for reviews, see [92,93]), this review will focus on the action of DA on 5HT and NE neurons in the DR and LC, respectively.”
BackgroundDhir, A., & Kulkarni, S. K. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.04.028 · Cited by 133 · cited 1×
“For instance, DA reuptake inhibitors, such as GBR12909 or bupropion, increase the time of immobility in the rat forced swimming test (FST) [40,51-55].”
BackgroundThe effects of tyrosine depletion in normal healthy volunteers: implications for unipolar depression
McLean, A., Rubinsztein, J. S., Robbins, T. W., & Sahakian, B. J. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1586-8 · Cited by 125 · cited 1×
“In these conditions, dysphoric and anhedonic symptoms appear in healthy volunteers, or are potentiated in depressed patients [36-39].”
BackgroundRole of monoamine transporters in mediating psychostimulant effects
Riddle, E. L., Fleckenstein, A. E., & Hanson, G. R. (2005) · The AAPS Journal · doi:10.1208/aapsj070481 · Cited by 117
Hippocampal cell proliferation regulation by repeated stress and antidepressants
Chen, H., Pandey, G. N., & Dwivedi, Y. (2006) · NeuroReport · doi:10.1097/01.wnr.0000221827.03222.70 · Cited by 115
El Mansari, M., Ghanbari, R., Janssen, S., & Blier, P. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.028 · Cited by 63 · cited 1×
“These findings appear consistent with electrophysiological studies showing that short- and long-term (but not acute) treatment with the DA reuptake inhibitor, bupropion, doubles the mean firing rate of 5-HT neurons compared to control rats [98-100].”
ResultTargeting TrkB neurotrophin receptor to treat depression
Rantamäki, T., & Castrén, E. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.6.705 · Cited by 40
Cited by
Psychomotor retardation in depression: Biological underpinnings, measurement, and treatment
Buyukdura, J. S., McClintock, S. M., & Croarkin, P. E. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.10.019 · Cited by 398
Baskerville, T. A., & Douglas, A. J. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00154.x · Cited by 377
Serotonergic Drugs for Depression and Beyond
M. Stahl, S., Lee-Zimmerman, C., Cartwright, S., & Ann Morrissette, D. (2013) · Current Drug Targets · doi:10.2174/1389450111314050007 · Cited by 272
Blood, A. J., Iosifescu, D. V., Makris, N., Perlis, R. H., Kennedy, D. N., Dougherty, D. D., Kim, B. W., Lee, M. J., Wu, S., Lee, S., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013945 · Cited by 126
“Clinically, our findings in the VTA/SN support hypotheses regarding involvement of the midbrain dopamine reward circuitry in MDD [7], and support investigation of interventions based thereon [91].”
BackgroundTran, P., Skolnick, P., Czobor, P., Huang, N. Y., Bradshaw, M., McKinney, A., & Fava, M. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2011.09.003 · Cited by 81
Metadata
- Authors
- Guiard, B., Mansari, M., & Blier, P.
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-11-01
- Volume
- 10
- Issue
- 11
- Pages
- 1069-1084
- ISSN
- 1389-4501 (ISSN-L)
- OpenAlex
- W2097053175
- Cited by
- 90
- References
- 35
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.